The approval was based on data from the phase 2/3 OSPREY and phase 3 CONDOR trials that evaluated the diagnostic performance and safety of Pylarify injection. The Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback